About Cytogen

Cytogen is a specialty pharmaceutical company dedicated to advancing the treatment and care of cancer patients by building, developing, and commercializing a portfolio of oncology products. The Company's specialized sales force currently markets QUADRAMET^® (samarium Sm-153 lexidronam injection), PROSTASCINT^® (capromab pendetide), and SOLTAMOX^™ (tamoxifen citrate) to the U.S. oncology market. QUADRAMET is approved for the treatment of pain in patients whose cancer has spread to the bone, PROSTASCINT is a PSMA-targeting monoclonal antibody-based agent to image the extent and spread of prostate cancer, and SOLTAMOX is the first liquid hormonal therapy approved in the U.S. for the treatment of breast cancer in adjuvant and metastatic settings. In early 2007, Cytogen introduced its fourth approved oncology product to the U.S. market, CAPHOSOL^®, an advanced electrolyte solution for the treatment of oral mucositis and dry mouth that is approved in the U.S. as a prescription medical device. The Company is also developing CYT-500, a third-generation radiolabeled antibody to treat prostate cancer. Cytogen's product-focused strategy focuses on attaining sustainable growth through clinical, commercial, and strategic initiatives.

Full prescribing information for the Company's products is available on this website or by calling 1-800-833-3533.